MRG002 is named as an intervention in 3 current clinical trials in our China and USA registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Shanghai Miracogen Inc (2). The most-studied condition is Advanced Solid Tumors.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
NCT05754853 · ClinicalTrials.gov ↗ · Advanced or Metastatic Urothelium Cancer
|
Phase 3 | Recruiting | Shanghai Miracogen Inc. | China |
|
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
NCT06869174 · ClinicalTrials.gov ↗ · Cancer of Unknown Primary
|
Phase 2 | Not yet open | Zhiguo Luo, MD, PhD | China |
|
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
NCT04492488 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
|
Phase 1/2 | Active, closed | Shanghai Miracogen Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Miracogen Inc. | 2 |
| Zhiguo Luo, MD, PhD | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and USA registers name MRG002 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Miracogen Inc (2) and Zhiguo Luo, MD, PhD (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how MRG002 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MRG002 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MRG002 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.